Lobbyist: Lawmakers Weigh Linking Reintroduced CREATES Bill To User Fees

House and Senate lawmakers are discussing ways to attach to FDA user fee legislation a newly reintroduced bill that would prevent brand drug makers from using Risk Evaluation and Mitigation Strategies to delay generics, a Democratic lobbyist tells Inside Health Policy . But the effort could face hurdles: The bipartisan Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act was reintroduced Thursday (April 27) as a separate group of lawmakers, which includes the House Energy & Commerce chairman,...